Thursday 7th September 2017
|Text too small?|
Alliance Group will invest $1.7 million in two plants in order to meet growing demand for New Zealand-sourced blood products.
In Pukeuri in Oamaru it will build a new facility created to help boost the recovery of blood-based products for sale to the pharmaceutical, biotechnology and medical device industries, the cooperative said in a statement. The meat processor will also improve the recovery of offal and upgrade the pet food area, it said.
Blood products are used in the development of vaccines, cancer treatments and drugs to treat neurodegenerative, haematological and endocrine disorders, according to Alliance. A spokesman said the cooperative supplies New Zealand companies that then sell to their own customers.
It will also invest in its Lorneville plant near Invercargill to extract more value from blood products. The cooperative has installed a laboratory-standard blood processing facility at the plant, it said.
Alliance, the world's largest processor and exporter of sheepmeat, had seen a "substantial lift" in demand from the pharmaceutical industry for New Zealand-sourced blood products, chief executive David Surveyor said.
“The range of beef offal captured at Pukeuri is currently limited due to the size of the space at the plant. Part of capturing more value is optimising the collection of blood products from processed animals. This upgrade will boost the capacity of our bovine offal and blood capture facilities significantly," he said.
New Zealand currently exports about $92 million of blood products to the European Union and $36.5 million to the US for pharmaceutical purposes each year, according to government figures, although the data doesn't differentiate between animal and human sources.
No comments yet
Government package for commercial leases too little, too late
Concerns over Government’s intervention in commercial leases
Development Commitment to Bowen Campus Stage Two
Vista Group International Limited - Update on the impacts of COVID-19
AFT secures Maxigesic IV® distribution in four Western European countries and reports Australasian market share gains in COVID-19 medicines
Investore Property Limited (Investore) today announced its financial results for the twelve months ended 31 March 2020 (FY20).
Rabobank GDT Analysis - Event 261
SkyCity Entertainment Group Limited - Update on COVID-19 Impacts and Recent Trading
ANZ announces sale of UDC Finance
Foley Wines Limited Announces Harvest Result, Earnings Outlook and Development in Martinborough